Rhopressa (netarsudil 0.02%) is a prescription eye drop approved by the FDA in December 2017 for lowering intraocular pressure in adults with open-angle glaucoma or ocular hypertension. The drug belongs to a class called rho kinase inhibitors, one of the first new glaucoma drug classes approved in over two decades.
Rhopressa works by inhibiting rho kinase (ROCK) to increase aqueous humor outflow through the trabecular meshwork while also reducing episcleral venous pressure. Clinical trials document IOP reductions of up to 5mmHg, comparable to timolol 0.5% twice daily. The drug pairs with latanoprost as the fixed-dose product Rocklatan for once-daily dosing.
But real-world patient ratings tell a different story. Rhopressa holds just a 2.4 out of 5 on WebMD, with only 28% of users reporting positive effects. This review covers how it works, its side effects, who should avoid it, and whether it’s really worth the price for glaucoma patients.
What Are Rhopressa Eye Drops?
Rhopressa is a prescription ophthalmic solution (netarsudil 0.02%) approved by the FDA in December 2017 for lowering intraocular pressure in adults with open-angle glaucoma and ocular hypertension. It belongs to a class called rho kinase inhibitors. The drug represents a genuinely new approach to glaucoma management.
Here’s the thing: Rhopressa is a rho kinase (ROCK) inhibitor developed by Aerie Pharmaceuticals. The drug class differs from older glaucoma treatments like timolol or prostaglandin analogs. That distinction matters for patients who haven’t responded to conventional first-line therapies.
The formulation contains 0.2mg/mL of netarsudil, supplied as a 2.5mL fill in a 4mL bottle. Administration involves topical application directly to the eye. The container design helps ensure accurate dosing with each use.
Quick Facts:
- Generic name: Netarsudil
- Drug class: Rho kinase (ROCK) inhibitor
- Manufacturer: Aerie Pharmaceuticals (now Alcon)
- FDA approval: December 2017
- Dosing: Once daily in the evening
What Is Rhopressa Used For?
Rhopressa is indicated for reducing elevated intraocular pressure in adults diagnosed with open-angle glaucoma or ocular hypertension, conditions where fluid accumulation pushes eye pressure beyond safe physiological limits. Uncontrolled IOP damages the optic nerve and leads to progressive vision loss.
In fact, eye care specialists increasingly use Rhopressa as a second-line therapy combined with prostaglandin analogs like latanoprost. The combination addresses patients where monotherapy fails to bring IOP to target levels. This role as an add-on agent defines most real-world prescribing patterns for the drug.
How Does Rhopressa Work?
Rhopressa works by inhibiting rho kinase (ROCK), which relaxes the trabecular meshwork to increase aqueous humor outflow through the eye’s primary drainage channel, directly lowering intraocular pressure. That outflow enhancement is the drug’s principal mechanism of action.
And here’s the best part: Rhopressa also lowers episcleral venous pressure, the pressure floor that determines the minimum IOP the eye can sustain physiologically. The episcleral effect gives Rhopressa the potential to reduce IOP to the low teens (12-14 mmHg or 0.47-0.55 inHg), and occasionally into single digits in rare cases.
Unlike most glaucoma medications that act through a single pathway, Rhopressa works through two complementary mechanisms simultaneously. The combined trabecular outflow enhancement and episcleral pressure reduction allow for greater IOP-lowering potential than single-pathway drugs achieve alone.
How Rhopressa Lowers Eye Pressure:
- Inhibits rho kinase (ROCK) enzyme in the trabecular meshwork.
- Trabecular meshwork cells relax. The drainage channel widens.
- Aqueous humor flows out more freely. Eye pressure drops as a result.
- Episcleral venous pressure also decreases as a secondary effect.
- Combined action lowers IOP toward target range.
What Are the Ingredients in Rhopressa?
Rhopressa contains netarsudil as its active ingredient at a concentration of 0.02% (0.2mg/mL), a rho kinase inhibitor specifically engineered for once-daily topical use in glaucoma patients. This concentration was selected through clinical development as the optimal therapeutic dose.
To be clear, netarsudil belongs to the rho kinase (ROCK) inhibitor drug class, a relatively new pharmacological category targeting the trabecular meshwork outflow pathway. The mechanism differs fundamentally from prostaglandins, which increase uveoscleral outflow, and beta-blockers, which reduce aqueous production. That class distinction makes Rhopressa complementary rather than redundant to existing treatments.
The 0.02% concentration of netarsudil was established through clinical trials as the balance point between efficacy and acceptable side effects. Higher concentrations increased IOP reduction but also amplified ocular side effects. The approved concentration optimizes therapeutic benefit while managing tolerability concerns for long-term use.
What Is Netarsudil?
Netarsudil is a dual-action rho kinase and norepinephrine transporter inhibitor that lowers IOP by increasing trabecular outflow and reducing episcleral venous pressure simultaneously. This dual action sets it apart mechanistically from prostaglandins and beta-blockers. The dual action explains Rhopressa’s unique pressure-lowering profile.
Here’s why this matters: Netarsudil was developed by Aerie Pharmaceuticals and gained FDA approval in December 2017. The approval made netarsudil one of the first genuinely new classes of glaucoma medication approved in over two decades. The development represented a significant pharmacological advance in glaucoma therapy options.
What Are the Benefits of Rhopressa Eye Drops?
Rhopressa reduces intraocular pressure by up to 5mmHg (0.19 inHg) from baseline according to clinical trials. The drug demonstrates efficacy comparable to timolol 0.5% twice daily for patients with baseline IOP under 25mmHg (0.97 inHg). The drug offers a novel mechanism where conventional therapies have proven insufficient.
Bottom line: Rhopressa is dosed once daily in the evening, which simplifies medication schedules compared to timolol’s twice-daily requirement. Adherence to glaucoma medications is notoriously poor among patients. Once-daily dosing reduces the burden and improves the likelihood of consistent use.
And it gets better: Rhopressa works synergistically with latanoprost, a prostaglandin analog, and the combination is available as the fixed-dose product Rocklatan. Rocklatan delivers both drugs in a single once-daily application. The fixed combination further simplifies treatment for patients requiring multiple glaucoma agents.
Rhopressa vs. Timolol Comparison:
| Feature | Rhopressa | Timolol 0.5% |
|---|---|---|
| Drug class | ROCK inhibitor | Beta-blocker |
| Dosing frequency | Once daily (evening) | Twice daily (morning) |
| IOP reduction | Up to 5mmHg | Up to 5-7mmHg |
| Mechanism | Increases outflow | Reduces production |
| Main side effects | Eye redness, corneal changes | Systemic (heart, lungs) |
| Generic available | Yes (netarsudil) | Yes |
Does Rhopressa Actually Lower Eye Pressure?
Yes. Rhopressa received FDA approval based on 3 randomized clinical trials documenting IOP reductions up to 5mmHg, with performance comparable to timolol 0.5% twice daily in patients with baseline pressures below 25mmHg (0.97 inHg). The clinical evidence for IOP-lowering efficacy is solid.
But here’s what no one tells you: real-world patient satisfaction data tells a more nuanced story. Rhopressa holds a 2.4 out of 5 average rating from 29 patient reviews on WebMD, with only 28% of reviewers reporting a positive effect. The gap between clinical trial data and real-world experience reflects the heavy impact of side effects on overall satisfaction.
Can Rhopressa Lower IOP to Normal Levels?
Yes. Rhopressa has the potential to reduce IOP to the low teens, approximately 12-14mmHg (0.47-0.55 inHg), and in rare cases into single digits, by targeting episcleral venous pressure as a secondary mechanism. This depth of IOP reduction isn’t achievable with many conventional glaucoma medications.
Normal IOP ranges from 10-21mmHg (0.39-0.82 inHg), and many glaucoma patients require pressures at the lower end to prevent progressive optic nerve damage. Rhopressa’s dual mechanism may benefit patients who need IOP below 15mmHg but haven’t achieved that goal with prostaglandin or beta-blocker monotherapy alone.
What Do Rhopressa Reviews Say?
Rhopressa has an average patient rating of 2.4 out of 5 from 29 reviews on WebMD, with approximately 28% of reviewers reporting a positive effect. The low score reflects mixed to poor real-world patient satisfaction despite strong clinical trial efficacy data. The low rating is primarily driven by side effect burden.
Eye care specialists describe Rhopressa as a ‘very nice medication’ for second-line combination therapy, particularly when paired with latanoprost. Physicians note its unique mechanism fills a real therapeutic gap. That said, those same specialists acknowledge insurance approval challenges as a significant barrier to patient access.
What Are the Positive Experiences With Rhopressa?
Patients who respond well to Rhopressa report meaningful IOP reduction that preserved vision where previous medications had failed to achieve adequate pressure control. The outcomes represent genuine therapeutic value for a subset of difficult-to-treat glaucoma patients. These successes tend to involve patients with specific IOP profiles.
Pay attention to this: ophthalmologists who prescribe Rhopressa cite its dual mechanism and potential for deeper IOP lowering as clinical advantages. The drug becomes particularly valuable for patients who need IOP below 15mmHg (0.58 inHg) to halt optic nerve damage. No other single-agent medication reliably reaches that target through the trabecular outflow pathway.
What Are the Common Complaints About Rhopressa?
Eye redness (conjunctival hyperemia) is the most frequently reported complaint among Rhopressa users. The majority of patients experience redness severe enough to cause social embarrassment and medication discontinuation. This side effect drives the bulk of poor patient ratings.
Insurance coverage difficulties represent the second most frequent complaint from both patients and prescribing physicians. Rhopressa often requires prior authorization and step therapy through older, cheaper medications before insurers approve coverage. This approval process delays treatment and frustrates patients who may benefit from Rhopressa specifically.
Here’s the kicker: with only 28% of reviewers reporting positive outcomes and a 2.4/5 rating, a significant proportion of patients discontinue Rhopressa before experiencing full therapeutic benefit. Side effects outweigh perceived benefits for many users. Discontinuation rates highlight the importance of patient counseling about expected side effects before starting treatment.
Common Complaints:
- Persistent eye redness (hyperemia) affecting daily life
- Difficulty getting insurance to cover the medication
- Eye discomfort and burning sensation after instillation
- Corneal deposits causing visual disturbances in some users
- High out-of-pocket cost without insurance coverage
What Are the Side Effects of Rhopressa?
Rhopressa commonly causes conjunctival hyperemia (eye redness), conjunctival hemorrhage (small blood spots), corneal verticillata (a whorl-like pattern on the cornea), and eye discomfort as its principal side effects, with hyperemia affecting the majority of users. These ocular effects are the defining tolerability challenge with this medication.
So, conjunctival hyperemia was the most frequently reported side effect in clinical trials. Most occurrences were rated by investigators as mild to moderate in severity. The prevalence and cosmetic impact of redness remain the primary reason patients and physicians discuss discontinuing Rhopressa therapy.
Corneal verticillata, a spiderly whorl-like pattern deposited in the corneal epithelium, occurs in some Rhopressa users. The corneal changes rarely affect visual acuity or functional eyesight according to clinical reports. The pattern typically resolves after medication is discontinued.
What Are the Most Common Side Effects?
The most common side effects of Rhopressa include conjunctival hyperemia (eye redness), conjunctival hemorrhage (tiny blood spots), corneal verticillata (whorl-like corneal deposits), blurred vision, instillation site pain, and corneal staining, with hyperemia occurring most frequently. These effects are primarily localized to the eye.
In clinical trials, the majority of hyperemia cases were graded as mild to moderate by investigators. Severe hyperemia occurred in a smaller proportion of patients. The severity grading is important context because mild redness, while cosmetically bothersome, doesn’t typically indicate a medical emergency or require immediate discontinuation.
Side Effect Frequency:
| Side Effect | Frequency | Severity |
|---|---|---|
| Conjunctival hyperemia (redness) | Very common | Mild to moderate |
| Conjunctival hemorrhage | Common | Mild |
| Corneal verticillata | Common | Mild (rarely affects vision) |
| Instillation site pain | Common | Mild |
| Blurred vision | Less common | Mild to moderate |
| Allergic reaction | Rare | Potentially serious |
What Are the Serious Side Effects?
Serious side effects of Rhopressa include significant corneal changes, severe conjunctival hemorrhage, and allergic hypersensitivity reactions, though these events are considerably less common than the typical mild-to-moderate ocular side effects seen in clinical trials. Awareness of these risks supports appropriate patient monitoring.
This is important: patients are advised to contact their eye care provider immediately if they experience severe eye pain, significant vision changes, or signs of allergic reaction such as eyelid swelling, facial rash, or difficulty breathing while using Rhopressa. Prompt reporting of serious symptoms allows for timely intervention. Self-managing these symptoms without professional guidance is not recommended.
Who Should Not Use Rhopressa?
Rhopressa is contraindicated in patients with known hypersensitivity to netarsudil or any component of the formulation, and extreme caution is warranted in patients with active ocular infections or significant pre-existing corneal disease. Prescribers evaluate individual patient history before initiating therapy.
Rhopressa carries pregnancy precautions because data on human use during pregnancy is limited. Women who are pregnant or planning to become pregnant should conduct a thorough risk-benefit discussion with their eye care provider before using Rhopressa. Breastfeeding mothers face similar considerations, as drug excretion into breast milk hasn’t been fully characterized.
The safety and effectiveness of Rhopressa in pediatric patients haven’t been established through clinical trials. The medication is currently approved for adult use only in glaucoma and ocular hypertension management. Children and adolescents should not receive Rhopressa outside of specialized clinical research settings.
Who Should Avoid Rhopressa:
- Patients allergic to netarsudil or any formulation ingredient
- Patients with active eye infections
- Pregnant or breastfeeding women (consult doctor first)
- Children and adolescents (not approved for pediatric use)
- Patients with severe pre-existing corneal disease
Is Rhopressa Safe and FDA Approved?
Yes. Rhopressa received FDA approval in December 2017 after 3 randomized controlled clinical trials confirmed its safety and efficacy for lowering intraocular pressure in adults with open-angle glaucoma and ocular hypertension. The approval process validated both its mechanism and safety profile.
The primary safety concern with Rhopressa is localized ocular side effects, particularly hyperemia and corneal changes. These effects are well-characterized and generally manageable with appropriate patient monitoring. Long-term use under regular eye care supervision is considered safe for appropriately selected patients.
Rhopressa may interact with other topical ophthalmic medications administered concurrently. Should you take multiple eye drops? Yes, but wait at least 5 minutes between them. The waiting interval prevents dilution of Rhopressa’s active ingredient and reduces potential for increased systemic absorption when multiple drops are applied in sequence.
How Much Does Rhopressa Cost?
Rhopressa carries a significant retail price without insurance coverage, with brand-name pricing typically ranging from approximately $200-$400 USD per month for the standard 2.5mL bottle. Insurance authorization is an important factor in patient access decisions. Out-of-pocket costs present a real barrier for many patients.
The good news? Alcon offers a Savings Card program for eligible patients that can significantly reduce out-of-pocket costs for Rhopressa prescriptions. Enrollment is available through the MyAlcon Together Patient Support program. Patients who qualify for commercial insurance savings cards may reduce monthly costs substantially, in some cases to near zero for eligible individuals.
Is Rhopressa Worth the Price?
Yes. The medication offers genuine therapeutic value for patients who respond well and achieve adequate IOP control, particularly those who’ve failed other glaucoma medications or require combination therapy to protect the optic nerve. Benefit must still be weighed against cost individually.
Here’s the part most people miss: only 28% of patients report positive outcomes in real-world reviews and insurance coverage is frequently difficult to obtain. The cost-benefit ratio for many patients is unfavorable compared to established alternatives. Generic timolol, for example, costs a fraction of Rhopressa’s price. Patients who don’t achieve IOP control on first-line agents are the best candidates for accepting Rhopressa’s higher cost.
Where Can You Buy Rhopressa?
Rhopressa is a prescription-only medication requiring a valid prescription from a licensed ophthalmologist or optometrist, and cannot be purchased over-the-counter or through non-prescription retail channels. The prescription requirement exists because appropriate diagnosis and monitoring are essential for safe use.
Once prescribed, Rhopressa is available at most major pharmacy chains throughout the United States. Patients can also use manufacturer coupons or pharmacy discount programs to reduce out-of-pocket costs at the point of dispensing. Mail-order pharmacy services may offer additional savings for patients on maintenance therapy.
Is Rhopressa Worth It?
For most patients, no. Rhopressa offers a novel IOP-lowering mechanism that benefits select patients needing deeper pressure reductions or combination therapy, but its 28% patient satisfaction rate and significant side effect burden position it as a second-line option, not a first-choice treatment. Clinical value is real but narrow in practice.
So who actually benefits? Rhopressa is most likely to deliver value for patients with open-angle glaucoma who have baseline IOP under 25mmHg (0.97 inHg), can’t tolerate or don’t respond adequately to prostaglandin analogs or beta-blockers, and require IOP lowering into the low teens to prevent optic nerve progression.
Eye care specialists consistently recommend Rhopressa as a second-line therapy to add to existing regimens rather than a first-choice medication. The decision to prescribe rests on individual patient response and tolerance for potential hyperemia. Patients who accept the likelihood of eye redness and work with their physician on monitoring stand the best chance of benefiting from Rhopressa’s unique mechanism.